Vyora provides compounded Semaglutide and Tirzepatide, two GLP-1 medications
Foeller E, Feldman DE (2004)
The product is functionally interchangeable with Hospira for the documented use case the USP specification ensures that compliant product from either manufacturer contains the same formulation at the same quality standard
NICE technology appraisal guidance TA875 recommends semaglutide for use within specialist weight management services, subject to specific eligibility criteria: a BMI of 35 kg/m or above, or a lower BMI threshold for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds, alongside at least one weight-related comorbidity, and as part of a specialist multidisciplinary programme
doi: 10.1016/J.SCP.2020.100218 185 van den HeuvelD